BFA
TBRA

BlackRock Fund Advisors’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

BlackRock Fund Advisors’s Portfolio TBRA Stock Details TBRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-238,580
Closed -$9.48M – 4302
2016
Q3 		$9.48M Buy
238,580
+10,805
+5% +$121K ﹤0.01% 2510
2016
Q2 		$2.86M Buy
227,775
+163,943
+257% +$1.53M ﹤0.01% 3093
2016
Q1 		$522K Sell
63,832
-3,585
-5% -$27K ﹤0.01% 3237
2015
Q4 		$678K Buy
67,417
+1,767
+3% +$18.4K ﹤0.01% 3254
2015
Q3 		$634K Buy
65,650
+9,694
+17% +$136K ﹤0.01% 3222
2015
Q2 		$965K Buy
55,956
+9,159
+20% +$134K ﹤0.01% 3211
2015
Q1 		$514K Sell
46,797
-339
-0.7% -$3.64K ﹤0.01% 3264
2014
Q4 		$387K Buy
47,136
+6,571
+16% +$56.6K ﹤0.01% 3314
2014
Q3 		$413K Sell
40,565
-1,680
-4% -$33.2K ﹤0.01% 3263
2014
Q2 		$2.58M Buy
+42,245
New +$2.57M ﹤0.01% 3099

BlackRock Fund Advisors's TBRA Position: Q4 2016 in Review

BlackRock Fund Advisors sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q4 2016, closing a stake of 238,580 shares — an estimated $9.48M sold.

BlackRock Fund Advisors first reported a position in TBRA in Q2 2014 and held it in 10 quarters. The position peaked at $9.48M in Q3 2016. 0 funds tracked by Wall St. Rank hold TBRA as of Q4 2016.

  • BlackRock Fund Advisors reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • BlackRock Fund Advisors sold 238,580 Tobira Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $9.48M.
  • BlackRock Fund Advisors first reported a position in Tobira Therapeutics, Inc. Common Stock in Q2 2014 and held it in 10 quarters.
  • BlackRock Fund Advisors's Tobira Therapeutics, Inc. Common Stock position peaked at $9.48M in Q3 2016.
  • 0 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.